Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

CompletedOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

June 16, 2023

Study Completion Date

June 16, 2023

Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Trial Locations (15)

Unknown

CHU Amiens - Hôpital Sud, Amiens

CHU d'Estaing, Clermont-Ferrand

APHP - Hopital Henri Mondor, Créteil

CHU Grenoble, Grenoble

CHRU de Lille - Hôpital Claude Huriez, Lille

Institut Paoli Calmette, Marseille

APHP - Hôpital Necker, Paris

APHP - Hôpital Saint Louis, Paris

CHU Bordeaux - Centre François Magendie, Pessac

Centre Hospitalier Lyon Sud, Pierre-Bénite

CHU de Rennes - Hôpital de Pontchaillou, Rennes

Centre Henri Becquerel, Rouen

CHRU de Strasbourg, Strasbourg

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse

CHU Brabois, Vandœuvre-lès-Nancy

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Hôpital Necker-Enfants Malades

OTHER

collaborator

Fondation ARC

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER

NCT03603847 - Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma | Biotech Hunter | Biotech Hunter